Spots Global Cancer Trial Database for Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
Official Title: A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer
Study ID: NCT00864175
Conditions
Study Description
Brief Summary: This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety of INCB007839 in combination with trastuzumab and docetaxel.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
, Visakhapatnam, Andhra Pradesh, India
, New Delhi, Ansari Nagar, India
, Mangalore, Attavar, India
, Bangalore, Karnataka, India
, Hyderabaad, Punjagutta, India
, Bangalore, Ram Nagar, India
, Delhi, Rohini, India
, Delhi, Vasundhara Enclave, India
, Bhopal, , India
, Kolkata, , India
, Nashik, , India
, Pune, , India
Contact Details
Name: Bijyoyesh Mookerjee, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
